Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-14T00:08:19.092Z Has data issue: false hasContentIssue false
  • English
  • Français

Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments

Published online by Cambridge University Press:  24 June 2014

Richard J. Porter  and
Peter Gallagher
Richard J. Porter*
Affiliation:
Department of Psychological Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Peter Gallagher
Affiliation:
School of Neurology, Neurobiology and Psychiatry, University of Newcastle, Newcastle upon Tyne, UK
*
Richard J. Porter, MB BS, MD, MA, DipObst, MRCPsych, Department of Psychological Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch 8140, New Zealand. Tel: +64-3-372-0400; Fax: +64-3-372-0407; E-mail: richard.porter@chmeds.ac.nz
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

New evidence is emerging regarding abnormalities of hypothalamic-pituitary-adrenal (HPA) axis function in subtypes of affective disorders. Adverse effects of HPA axis dysregulation may include dysfunction of monoaminergic transmitter systems, cognitive impairment and peripheral effects. Newer treatments specifically targeting the HPA axis are being developed.

Objective:

To review these developments focusing particularly on the glucocorticoid receptor (GR) antagonist mifepristone.

Method:

A selective review of the literature.

Results:

The function of GRs is increasingly being defined. The role of corticotrophin-releasing hormone (CRH) and dehydroepiandrosterone (DHEA) in the brain is also increasingly understood. HPA axis function is particularly likely to be abnormal in psychotic depression and bipolar disorder, and it is in these conditions that trials of the GR antagonist mifepristone are being focused. CRH antagonists and DHEA are also being investigated as potential treatments.

Conclusion:

Initial studies of mifepristone and other HPA-axis-targeting agents in psychotic depression and bipolar disorder are encouraging and confirmatory studies are awaited.

Keywords

bipolar disordercortisolCRHdepressionDHEAhypothalamic-pituitary-adrenal axismifepristone
Type
Review Article
Information
Acta Neuropsychiatrica , Volume 18 , Issue 5 , October 2006 , pp. 193 - 209
Copyright
Copyright © 2006 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gibbons, JL. Cortisol secretion rate in depressive illness. Arch Gen Psychiatry 1964;10:572–575. Google Scholar
Vale, W, Spiess, J, Rivier, C, Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394–1397. Google Scholar
Plotsky, PM. Pathways to the secretion of adrenocorticotropin: a view from the portal. J Neuroendocrinol 1991;3:1–9. Google Scholar
Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999;33:181–214. Google Scholar
Steiger, A, Holsboer, F. Neuropeptides and human sleep. Sleep 1997;20:1038–1052. Google Scholar
Beato, M. Gene regulation by steroid hormones. Cell 1989;56:335–344. Google Scholar
Antoni, FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993;14:76–122. Google Scholar
Tilders, FJH, Schmidt, ED, De Goeij, DCE. Phenotypic plasticity of CRF neurons during stress. Ann N Y Acad Sci 1993;697:39–52. Google Scholar
Keck, ME, Hatzinger, M, Wotjak, CT, Landgraf, R, Holsboer, F, Neumann, ID. Ageing alters intrahypothalamic release patterns of vasopressin and oxytocin in rats. Eur J Neurosci 2000;12:1487–1494. Google Scholar
Raadsheer, FC, Hoogendijk, WJG, Stam, FC, Tilders, FJH, Swaab, DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436–444. Google Scholar
Keck, ME, Wigger, A, Welt, Tet al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002;26:94–105. Google Scholar
Young, EA, Kotun, J, Haskett, RFet al. Dissociation between pituitary and adrenal suppression to dexamethasone in depression. Arch Gen Psychiatry 1993;50:395–403. Google Scholar
Hellman, L, Nakada, F, Curti, Jet al. Cortisol is secreted episodically by normal man. J Clin Endocrinol Metab 1970;30:411–422. Google Scholar
Nishida, S, Matsumura, S, Horino, M, Oyama, H, Tenku, A. The variations of plasma corticosterone/cortisol ratios following ACTH stimulation or dexamethasone administration in normal men. J Clin Endocrinol Metab 1977;45:585–588. Google Scholar
Karssen, AM, Meijer, OC, Van Der Sandt, ICJet al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001;142:2686–2694. Google Scholar
Arriza, JL, Weinberger, C, Cerelli, Get al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268–275. Google Scholar
Reul, JM, De Kloet, ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505–2511. Google Scholar
Patel, PD, Sherman, TG, Goldman, DJ, Watson, SJ. Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol 1989;3:1877–1885. Google Scholar
Evans, RM, Arriza, JL. A molecular framework for the actions of glucocorticoid hormones in the nervous system. Neuron 1989;2:1105–1112. Google Scholar
Patel, PD, Lopez, JF, Lyons, DM, Burke, S, Wallace, M, Schatzberg, AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 2000;34:383–392. Google Scholar
Van Eekelen, JA, Jiang, W, De Kloet, ER, Bohn, MC. Distribution of the mineralocorticoid and the glucocorticoid receptor mRNAs in the rat hippocampus. J Neurosci Res 1988;21:88–94. Google Scholar
Sulcova, J, Hill, M, Hampl, R, Starka, L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. J Endocrinol 1997;154:57–62. Google Scholar
Herbert, J. Fortnightly review. Stress, the brain, and mental illness. BMJ 1997;315:530–535. Google Scholar
Herbert, J. The age of dehydroepiandrosterone. Lancet 1995;345:1193–1194. Google Scholar
Herbert, J. Neurosteroids, brain damage, and mental illness. Exp Gerontol 1998;33:713–727. Google Scholar
Cardounel, A, Regelson, W, Kalimi, M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med 1999;222:145–149. Google Scholar
Wolf, OT, Koster, B, Kirschbaum, Cet al. A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels. Biol Psychiatry 1997;42:845–848. Google Scholar
Ueda, K, Okamura, N, Hirai, Met al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267:24248–24252. Google Scholar
Hoffmeyer, S, Burk, O, Von Richter, Oet al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473–3478. Google Scholar
Meijer, OC, De Lange, EC, Breimer, DD, De Boer, AG, Workel, JO, De Kloet, ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998;139:1789–1793. Google Scholar
Watson, S, Gallagher, P, Ritchie, JC, Ferrier, IN, Young, AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496–502. Google Scholar
Sapolsky, R. Stress, the ageing brain and the mechanism of neuron death. Cambridge, MA: MIT Press; 1992. Google Scholar
Carroll, BJ, Curtis, GC, Mendels, J. Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol Med 1976;6:235–244. Google Scholar
Carroll, BJ, Curtis, GC, Davies, BM, Mendels, J, Sugerman, AA. Urinary free cortisol excretion in depression. Psychol Med 1976;6:43–50. Google Scholar
Brouwer, JP, Appelhof, BC, Hoogendijk, WJGet al. Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur J Endocrinol 2005;152:185–191. Google Scholar
Gartside, SE, Leitch, MM, Young, AH. Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharmacology 2003;28:1572–1578. Google Scholar
Sachar, EJ, Hellman, L, Roffwarg, HP, Halpern, FS, Fukushima, DK, Gallagher, TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1973;28:19–24. Google Scholar
Deuschle, M, Schweiger, U, Weber, Bet al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234–238. Google Scholar
Halbreich, U, Asnis, GM, Shindledecker, R, Zumoff, B, Nathan, RS. Cortisol secretion in endogenous depression. I. Basal plasma levels. Arch Gen Psychiatry 1985;42:904–908. Google Scholar
Linkowski, P, Mendlewicz, J, Leclercq, Ret al. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985;61:429–438. Google Scholar
Young, EA, Carlson, NE, Brown, MB. Twenty-four-hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacology 2001;25:267–276. Google Scholar
Pfohl, B, Sherman, B, Schlechte, J, Stone, R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985;42:897–903. Google Scholar
Jarrett, DB, Coble, PA, Kupfer, DJ. Reduced cortisol latency in depressive illness. Arch Gen Psychiatry 1983;40:506–511. Google Scholar
Halbreich, U, Asnis, GM, Shindledecker, R, Zumoff, B, Nathan, RS. Cortisol secretion in endogenous depression. II. Time-related functions. Arch Gen Psychiatry 1985;42:909–914. Google Scholar
Claustrat, B, Chazot, G, Brun, J, Jordan, D, Sassolas, G. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984;19:1215–1228. Google Scholar
Rubin, R, Poland, R, Lesser, I, Winston, R, Blodgett, N. Neuroendocrine aspects of primary endogenous depression, cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry 1987;44:328–336. Google Scholar
Sherman, B, Pfohl, B, Winokur, G. Circadian analysis of plasma cortisol levels before and after dexamethasone administration in depressed patients. Arch Gen Psychiatry 1984;41:271–275. Google Scholar
Strickland, PL, Deakin, JF, Percival, C, Dixon, J, Gater, RA, Goldberg, DP. Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br J Psychiatry 2002;180:168–173. Google Scholar
Young, EA, Haskett, RF, Grunhaus, Let al. Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Arch Gen Psychiatry 1994;51:701–707. Google Scholar
Rubin, RT, Phillips, JJ, Sadow, TF, McCracken, JT. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995;52:213–218. Google Scholar
Krishnan, KRR, Doraiswamy, PM, Lurie, SNet al. Pituitary size in depression. J Clin Endocrinol Metab 1991;72:256–259. Google Scholar
Axelson, DA, Doraiswamy, PM, Boyko, OBet al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res 1992;44:63–70. Google Scholar
Carroll, BJ, Feinberg, M, Greden, JFet al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15–22. Google Scholar
Maguire, KP, Schweitzer, I, Biddle, N, Bridge, S, Tiller, JW. The dexamethasone suppression test: importance of dexamethasone concentrations. Biol Psychiatry 1987;22:957–967. Google Scholar
Wiedemann, K, Holsboer, F. The effect of dexamethasone dosage upon plasma cortisol and dexamethasone during the DST. J Affect Disord 1990;19:133–137. Google Scholar
O’Sullivan, BT, Hunt, GE, Johnson, GF, Caterson, ID. The plasma dexamethasone window: evidence supporting its usefulness to validate dexamethasone suppression test results. Biol Psychiatry 1989;25:739–754. Google Scholar
Heuser, I, Yassouridis, A, Holsboer, F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341–356. Google Scholar
Holsboer, F, Lauer, CJ, Schreiber, W, Krieg, JC. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;62:340–347. Google Scholar
von Bardeleben, U, Holsboer, F, Stalla, GK, Muller, OA. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 1985;37:1613–1618. Google Scholar
Zobel, AW, Nickel, T, Sonntag, A, Uhr, M, Holsboer, F, Ising, M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 2001;35:83–94. Google Scholar
Ribeiro, SC, Tandon, R, Grunhaus, L, Greden, JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:1618–1629. Google Scholar
Nemeroff, CB, Widerlov, E, Bissette, Get al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342–1344. Google Scholar
De Bellis, MD, Gold, PW, Geracioti, TD, Listwak, SJ, Kling, MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993;150:656–657. Google Scholar
Geracioti, TD Jr, Orth, DN, Ekhator, NN, Blumenkopf, B, Loosen, PT. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992;74:1325–1330. Google Scholar
Geracioti, TD, Loosen, PT, Orth, DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997;42:165–174. Google Scholar
Wong, ML, Kling, MA, Munson, PJet al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A 2000;97:325–330. Google Scholar
Gold, PW, Chrousos, G, Kellner, Cet al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984;141:619–627. Google Scholar
Gold, PW, Loriaux, DL, Roy, Aet al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314:1329–1335. Google Scholar
Holsboer, F, Von Bardeleben, U, Gerken, A, Stalla, GK, Muller, OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984;311:1127. Google Scholar
Holsboer, F, Gerken, A, Von Bardeleben, Uet al. Human corticotropin-releasing hormone in depression-correlation with thyrotropin secretion following thyrotropin-releasing hormone. Biol Psychiatry 1986;21:601–611. Google Scholar
Gold, PW, Licinio, J, Wong, ML, Chrousos, GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci 1995;771:716–729. Google Scholar
Lisansky, J, Peake, GT, Strassman, RJet al. Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pretreated with metyrapone. Arch Gen Psychiatry 1989;46:641–649. Google Scholar
Young, EA, Akil, H, Haskett, RF, Watson, SJ. Evidence against changes in corticotroph CRF receptors in depressed patients. Biol Psychiatry 1995;37:355–363. Google Scholar
Nemeroff, CB, Owens, MJ, Bissette, G, Andorn, AC, Stanley, M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577–579. Google Scholar
Leake, A, Perry, EK, Perry, RH, Fairbairn, AF, Ferrier, IN. Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression. Biol Psychiatry 1990;28:603–608. Google Scholar
Hucks, D, Lowther, S, Crompton, MR, Katona, CL, Horton, RW. Corticotropin-releasing factor binding sites in cortex of depressed suicides. Psychopharmacology (Berl) 1997;134:174–178. Google Scholar
Raadsheer, FC, Tilders, FJ, Swaab, DF. Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone neurons in controls and Alzheimer patients. J Neuroendocrinol 1994;6:131–133. Google Scholar
Purba, JS, Hoogendijk, WJG, Hofman, MA, Swaab, DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137–143. Google Scholar
Michael, A, Jenaway, A, Paykel, ES, Herbert, J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry 2000;48:989–995. Google Scholar
Young, AH, Gallagher, P, Porter, RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry 2002;159:1237–1239. Google Scholar
Goodyer, IM, Herbert, J, Altham, PM. Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med 1998;28:265–273. Google Scholar
Rush, AJ, Giles, DE, Schlesser, MAet al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996;57:470–484. Google Scholar
Rybakowski, JK, Twardowska, K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res 1999;33:363–370. Google Scholar
Schmider, J, Lammers, CH, Gotthardt, U, Dettling, M, Holsboer, F, Heuser, IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995;38:797–802. Google Scholar
Watson, S, Gallagher, P, Ferrier, IN, Young, A. Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. J Psychiatr Res 2006;40:353–359. Google Scholar
Knable, MB, Torrey, EF, Webster, MJ, Bartko, JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2004;55:651–659. Google Scholar
Lopez, JF, Little, KY, Lopez-Figueroa, AL, Lopez-Figueroa, MO, Watson, SJ. Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry 2003;53:489. Google Scholar
Webster, MJ, Knable, MB, O’Grady, J, Orthmann, J, Weickert, CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002;7:985–994. Google Scholar
Watson, S, Gallagher, P, Del-Estal, D, Hearn, A, Ferrier, IN, Young, AH. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychol Med 2002;32:1021–1028. Google Scholar
Nelson, JC, Davis, JM. DST studies in psychotic depression: a meta analysis. Am J Psychiatry 1997;154:1497–1503. Google Scholar
Posener, JA, Debattista, C, Williams, GH, Chmura Kraemer, H, Kalehzan, BM, Schatzberg, AF. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000;57:755–760. Google Scholar
Keller, J, Flores, BH, Gomez, RGet al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006;60:275–281. Google Scholar
Maes, M, Schotte, C, D’Hondt, Pet al. Biological heterogeneity of melancholia: results of pattern recognition methods. J Psychiatr Res 1991;25:95–108. Google Scholar
Maes, M, Calabrese, J, Meltzer, HY. The relevance of the in- versus outpatient status for studies on HPA-axis in depression: spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression per se. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:503–517. Google Scholar
Roth, M, Gurney, C, Mountjoy, CQ. The Newcastle rating scales. Acta Psychiatr Scand Suppl 1983;310:42–54. Google Scholar
Parker, G, Hadzi-Pavlovic, D, Wilhelm, Ket al. Defining melancholia: properties of a refined sign-based measure. Br J Psychiatry 1994;164:316–326. Google Scholar
Zimmerman, M, Coryell, W, Pfohl, B. The validity of the dexamethasone suppression test as a marker for endogenous depression. Arch Gen Psychiatry 1986;43:347–355. Google Scholar
Klein, HE, Bender, W, Mayr, H, Niederschweiberer, A, Schmauss, M. The DST and its relationship to psychiatric diagnosis, symptoms and treatment outcome. Br J Psychiatry 1984;145:591–599. Google Scholar
Brown, RP, Stoll, PM, Stokes, PEet al. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res 1988;23:167–178. Google Scholar
Mitchell, P. Validity of the CORE: I. A neuroendocrinological strategy. In: Parker, G, Hadzi-Pavlovic, D, eds. Melancholia: a disorder of movement and mood. Cambridge: Cambridge University Press, 1996: 138–148. Google Scholar
Pariante, CM, Vassilopoulou, K, Velakoulis, Det al. Pituitary volume in psychosis. Br J Psychiatry 2004;185:5–10. Google Scholar
Pariante, CM, Dazzan, P, Danese, Aet al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005;30:1923–1931. Google Scholar
Garner, B, Pariante, CM, Wood, SJet al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005;58:417–423. Google Scholar
Steen, RG, Mull, C, McClure, R, Hamer, RM, Lieberman, JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510–518. Google Scholar
Pantelis, C, Velakoulis, D, McGorry, PDet al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003;361:281–288. Google Scholar
, Porter RJ. Editorial: The hypothalamic-pituitary-adrenal axis: a target for intervention in early psychosis? Aust N Z J Psychiatry 2006;40:722–724. Google Scholar
Chaouloff, F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Brain Res Rev 1993;18:1–32. Google Scholar
Chaouloff, F. Serotonin, stress and corticoids. J Psychopharmacol 2000;14:139–151. Google Scholar
Dinan, TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry 1994;164:365–371. Google Scholar
McAllister-Williams, RH, Ferrier, IN, Young, AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med 1998;28:573–584. Google Scholar
Maes, M, Meltzer, HY. The serotonin hypothesis of major depression. In: Bloom, FE, Kupfer, DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, Ltd, 1995: 933–944. Google Scholar
Porter, RJ, Gallagher, P, Watson, S, Young, AH. Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacology (Berl) 2004;173:1–17. Google Scholar
Porter, RJ, Gallagher, P, Watson, S, Lunn, BS, Young, AH. The effects of sub-chronic administration of hydrocortisone on hormonal and psychological responses to L-tryptophan in normal male volunteers. Psychopharmacology (Berl) 2002;163:68–75. Google Scholar
Porter, RJ, McAllister-Williams, RH, Jones, S, Young, AH. Effects of dexamethasone on neuroendocrine and psychological responses to L-tryptophan infusion. Psychopharmacology (Berl) 1999;143:64–71. Google Scholar
Porter, RJ, McAllister-Williams, RH, Lunn, BS, Young, AH. 5-Hydroxytryptamine receptor function in man is reduced by acute administration of hydrocortisone. Psychopharmacology (Berl) 1998;139:243–250. Google Scholar
Bhagwagar, Z, Hafizi, S, Cowen, PJ. Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients. J Affect Disord 2002;72:249–255. Google Scholar
Bhagwagar, Z, Montgomery, AJ, Grasby, PM, Cowen, PJ. Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. Biol Psychiatry 2003;54:890–895. Google Scholar
Montgomery, AJ, Bench, CJ, Young, AHet al. PET measurement of the influence of corticosteroids on serotonin-1A receptor number. Biol Psychiatry 2001;50:668–676. Google Scholar
Schatzberg, AF, Rothschild, AJ, Langlais, PJ, Bird, ED, Cole, JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985;19:57–64. Google Scholar
Rothschild, AJ, Langlais, PJ, Schatzberg, AF, Walsh, FX, Cole, JO, Bird, ED. Dexamethasone increases plasma free dopamine in man. J Psychiatr Res 1984;18:217–223. Google Scholar
Wolkowitz, OM, Sutton, ME, Doran, ARet al. Dexamethasone increases plasma HVA but not MHPG in normal humans. Psychiatry Res 1985;16:101–109. Google Scholar
Lupien, SJ, Gaudreau, S, Tchiteya, BMet al. Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. J Clin Endocrinol Metab 1997;82:2070–2075. Google Scholar
Kirschbaum, C, Wolf, OT, May, M, Wippich, W, Hellhammer, DH. Stress and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sci 1996;58:1475–1483. Google Scholar
Beckwith, BE, Petros, TV, Scaglione, C, Nelson, J. Dose-dependent effects of hydrocortisone on memory in human males. Physiol Behav 1986;36:283–286. Google Scholar
Fehm-Wolfsdorf, G, Reutter, K, Zenz, H, Born, J, Fehm, HL. Are circadian variations in taste thresholds cortisol-dependant? J Psychophysiol 1993;7:65–72. Google Scholar
Porter, RJ, Barnett, NA, Idey, A, McGuckin, EA, O’Brien, JT. Effects of hydrocortisone administration on cognitive function in the elderly. J Psychopharmacol 2002;16:65–71. Google Scholar
Newcomer, JW, Selke, G, Melson, AKet al. Decreased memory performance in healthy humans induced by stress level cortisol treatment. Arch Gen Psychiatry 1999;56:527–533. Google Scholar
Young, AH, Sahakian, BJ, Robbins, TW, Cowen, PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) 1999;145:260–266. Google Scholar
Mauri, M, Sinforiani, E, Bono, Get al. Memory impairment in Cushing’s disease. Acta Neurol Scand 1993;87:52–55. Google Scholar
Starkman, MN, Schteingart, DE. Neuropsychiatric manifestations of patients with Cushing’s syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 1981;141:215–219. Google Scholar
de Quervain, DJ, Roozendaal, B, Nitsch, RM, McGaugh, JL, Hock, C. Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci 2000;3:313–314. Google Scholar
de Quervain, DJ, Henke, K, Aerni, Aet al. Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. Eur J Neurosci 2003;17:1296–1302. Google Scholar
Lupien, SJ, Gillin, CJ, Hauger, RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 1999;113:420–430. Google Scholar
Jelici, M, Geraerts, E, Merckelbach, H, Guerrieri, R. Acute stress enhances memory for emotional words, but impairs memory for neutral words. Int J Neurosci 2004;114:1343–1351. Google Scholar
Wolf, OT, Kuhlmann, S, Buss, C, Hellhammer, DH, Kirschbaum, C. Cortisol and memory retrieval in humans: influence of emotional valence. Ann N Y Acad Sci 2004;1032:195–197. Google Scholar
Kuhlmann, S, Wolf, OT. Arousal and cortisol interact in modulating memory consolidation in healthy young men. Behav Neurosci 2006;120:217–223. Google Scholar
Maheu, FS, Collicutt, P, Kornik, R, Moszkowski, R, Lupien, SJ. The perfect time to be stressed: a differential modulation of human memory by stress applied in the morning or in the afternoon. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1281–1288. Google Scholar
O’Brien, JT, Schweitzer, I, Ames, D, Tuckwell, V, Mastwyk, M. Cortisol suppression by dexamethasone in the healthy elderly: effects of age, dexamethasone levels, and cognitive function. Biol Psychiatry 1994;36:389–394. Google Scholar
Mitchell, AJ. The contribution of hypercortisolaemia to the cognitive decline of geriatric depression. Int J Geriatr Psychiatry 1995;10:401–409. Google Scholar
Wauthy, J, Ansseau, M, Von Frenckell, R, Mormont, C, Legros, JJ. Memory disturbances and dexamethasone suppression test in major depression. Biol Psychiatry 1991;30:736–738. Google Scholar
Rubinow, DR, Post, RM, Savard, R, Gold, PW. Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry 1984;41:279–283. Google Scholar
Porter, RJ, Gallagher, P, Thompson, JM, Young, AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003;182:214–220. Google Scholar
Watson, S, Thompson, JM, Ritchie, JC, Nicol Ferrier, I, Young, AH. Neuropsychological impairment in bipolar disorder: the relationship with glucocorticoid receptor function. Bipolar Disord 2006;8:85–90. Google Scholar
Gould, E, McEwen, BS. Neuronal birth and death. Curr Opin Neurobiol 1993;3:676–682. Google Scholar
Brown, ES, J Woolston, D, Frol, Aet al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 2004;55:538–545. Google Scholar
Starkman, MN, Giordani, B, Gebarski, SS, Berent, S, Schork, MA, Schteingart, DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry 1999;46:1595–1602. Google Scholar
Vythilingam, M, Vermetten, E, Anderson, GMet al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 2004;56:101–112. Google Scholar
O’Brien, JT, Lloyd, A, McKeith, I, Gholkar, A, Ferrier, N. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 2004;161:2081–2090. Google Scholar
Berne, RM, Levy, MN. Physiology. 4th edn. St Louis: Mosby Inc., 1998. Google Scholar
Thakore, JH, Richards, PJ, Reznek, RH, Martin, A, Dinan, TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 1997;41:1140–1142. Google Scholar
Weber-Hamann, B, Hentschel, F, Kniest, Aet al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002;64:274–277. Google Scholar
Vrkljan, M, Thaller, V, Lovricevic, Iet al. Depressive disorder as possible risk factor of osteoporosis. Coll Antropol 2001;25:485–492. Google Scholar
O’Brien, SM, Scott, LV, Dinan, TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004;19:397–403. Google Scholar
Pepin, MC, Beaulieu, S, Barden, N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 1989;6:77–83. Google Scholar
McQuade, R, Young, AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry 2000;177:390–395. Google Scholar
Barden, N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999;24:25–39. Google Scholar
Seckl, JR, Fink, G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55:621–626. Google Scholar
Rossby, SP, Nalepa, I, Huang, Met al. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res 1995;687:79–82. Google Scholar
Pariante, CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004;7:209–219. Google Scholar
Pariante, CM, Thomas, SA, Lovestone, S, Makoff, A, Kerwin, RW. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2004;29:423–447. Google Scholar
Pariante, CM. The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol 2006;20:79–84. Google Scholar
Gallagher, P, Young, AH. Mifepristone (RU-486) treatment of depression and psychosis: a review of the therapeutic implications. Neuropsychiatric Dis Treat 2006;2:33–42. Google Scholar
Pariante, CM. Depression, stress and the adrenal axis. J Neuroendocrinol 2003;15:811–812. Google Scholar
Greden, JF, Gardner, R, King, D, Grunhaus, L, Carroll, BJ, Kronfol, Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983;40:493–500. Google Scholar
Holsboer-Trachsler, E, Stohler, R, Hatzinger, M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991;38:163–171. Google Scholar
Inder, WJ, Prickett, TC, Mulder, RT, Donald, RA, Joyce, PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl) 2001;156:73–78. Google Scholar
Jahn, H, Schick, M, Kiefer, F, Kellner, M, Yassouridis, A, Wiedemann, K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004;61:1235–1244. Google Scholar
Arana, GW, Forbes, RA. Dexamethasone for the treatment of depression: a preliminary report J Clin Psychiatry 1991;52:304–306. Google Scholar
Arana, GW, Santos, AB, Laraia, MTet al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995;152:265–267. Google Scholar
O’Dwyer, AM, Lightman, SL, Marks, MN, Checkley, SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995;33:123–128. Google Scholar
Wolkowitz, OM, Reus, VI, Chan, Tet al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999;45:1070–1074. Google Scholar
Ghadirian, AM, Engelsmann, F, Dhar, Vet al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995;37:369–375. Google Scholar
Dinan, TG, Lavelle, E, Cooney, Jet al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997;95:58–61. Google Scholar
Hoyberg, O, Wik, G, Mehtonen, OP, Peeters, BW, Sennef, C. ORG 34517, a selective glucocrticoid receptor antagonist with potent antidepressant activity: first clinical results. Int J Neuropsychopharmacol 2002;5:S148. Google Scholar
Wolkowitz, OM, Reus, VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698–711. Google Scholar
Sonino, N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812–818. Google Scholar
Zobel, AW, Nickel, T, Kunzel, HEet al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171–181. Google Scholar
Bloch, M, Schmidt, PJ, Danaceau, MA, Adams, LF, Rubinow, DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533–1541. Google Scholar
Schmidt, PJ, Daly, RC, Bloch, Met al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154–162. Google Scholar
Huppert, FA, Van Niekerk, JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev 2001;2:CD000304. Google Scholar
Murphy, BE, Filipini, D, Ghadirian, AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18:209–213. Google Scholar
Belanoff, JK, Flores, BH, Kalezhan, M, Sund, B, Schatzberg, AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001;21:516–521. Google Scholar
Belanoff, JK, Rothschild, AJ, Cassidy, Fet al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52:386–392. Google Scholar
Simpson, GM, El Sheshai, A, Loza, Net al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 2005;66:598–602. Google Scholar
Debattista, C, Belanoff, J, Glass, Set al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006 Aug 4; [Epub ahead of print].Google Scholar
Young, AH, Gallagher, P, Watson, S, Del-Estal, D, Owen, BM, Nicol Ferrier, I. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29:1538–1545. Google Scholar
Mackin, P, Gallagher, P, Froom, K, Geddes, J, Young, A. Antiglucocorticoid treatments in mood disorders: efficacy and safety [protocol]. Cochrane Database Syst Rev 2005;1. Google Scholar
Bachmann, CG, Linthorst, AC, Holsboer, F, Reul, JM. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 2003;28:1056–1067. Google Scholar
Young, EA, Lopez, JF, Murphy-Weinberg, V, Watson, SJ, Akil, H. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 2003;60:24–28. Google Scholar
Juruena, MF, Papadopoulos, A, Cleare, AJ, Poon, L, Lightman, S, Pariante, CM. Treatment resistant depression: different response to dexamethasone and prednisolone test. 2005 ENCP Hot Topic Award. Eur Neuropsychopharmacol 2005;15:414. Google Scholar
Lupien, SJ, McEwen, BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev 1997;24:1–27. Google Scholar